Cecilia Jones
Director of Finance/CFO at AGIOS PHARMACEUTICALS, INC.
Net worth: 469 983 $ as of 2024-04-29
Cecilia Jones active positions
| Companies | Position | Start | End |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. | Director of Finance/CFO | 2022-09-25 | - |
Career history of Cecilia Jones
Former positions of Cecilia Jones
| Companies | Position | Start | End |
|---|---|---|---|
| LOGICBIO THERAPEUTICS, INC. | Comptroller/Controller/Auditor | - | 2022-09-22 |
| Director of Finance/CFO | 2021-01-10 | 2022-09-22 | |
| Investor Relations Contact | 2021-01-10 | 2022-09-22 | |
| Treasurer | - | 2022-09-22 | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 2002-12-31 | 2009-10-31 |
| BIOGEN INC. | Corporate Officer/Principal | 2015-06-30 | - |
Training of Cecilia Jones
| Harvard Business School | Masters Business Admin |
Statistics
International
| United States | 6 |
Operational
| Director of Finance/CFO | 2 |
| Corporate Officer/Principal | 2 |
| Comptroller/Controller/Auditor | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| BIOGEN INC. | Health Technology |
| AGIOS PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
LogicBio Therapeutics, Inc.
 LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Cecilia Jones
- Experience
